Tin tức & Cập nhật

Tavapadon, a novel, investigational, selective D1/D5 agonist with once-daily oral dosing, provides clinically meaningful and sustained benefit adjunctive to levodopa and has a favourable safety profile in patients with Parkinson’s disease (PD) experiencing off fluctuations, according to findings of the TEMPO-3 trial.

Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a lower risk of developing various incident substance use disorders (SUDs), suggests a study involving US veterans with type 2 diabetes (T2D). Its use also protects against adverse clinical outcome in people with pre-existing SUDs.

A recent study has shown how large language models (LLMs) treat patient tone as clinical input, leading to adjustments in triage, follow-up, prescribing, and sick-leave decisions despite identical symptoms.

In the treatment of iron-deficiency anaemia in pregnancy, the use of intravenous (IV) ferumoxytol appears to lead to greater improvements in haemoglobin at delivery and more frequent resolution of anaemia compared with oral ferrous sulfate, according to an open-label randomized controlled trial.

In the treatment of children with idiopathic steroid-sensitive nephrotic syndrome, mycophenolate mofetil demonstrates noninferiority to prednisone in maintaining remission and reducing subsequent relapse, with the added benefit of reduced glucocorticoid-related toxic effects, according to the open-label phase III INTENT trial.

In adult patients with diabetes and epilepsy, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with lower risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies, according to a retrospective study.

Treatment with the selective KRAS G12C inhibitor adagrasib significantly improves survival and yields high response rates in patients with KRAS G12C-mutant solid tumours, a study has shown.

In neonates with acute provoked seizures, continued use of antiseizure medications (ASMs) even after resolution of seizures may be unnecessary, as shown in a prospective, comparative effectiveness study.

In postmenopausal women receiving treatment with tirzepatide for overweight or obesity, concurrent use of hormone therapy confers greater reduction in weight as well as improvement in cardiometabolic outcomes, according to a retrospective cohort study.